Название продукции:3-methyl-5-[(8R)-8-methyl-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-3-yl]-1,2,4-thiadiazole

IUPAC Name:3-methyl-5-[(8R)-8-methyl-5H,6H,7H,8H-[1,2,4]triazolo[4,3-a]pyrazin-3-yl]-1,2,4-thiadiazole

CAS:1429558-08-6
Молекулярная формула:C9H12N6S
Чистота:95%+
Номер в каталоге:CM1044501
Молекулярная масса:236.3

Упаковочная единица Доступно для заказа Цена ($) Количество

Только для использования в НИОКР..

Форма запроса

   refresh    

Информация о продукции

Номер CAS:1429558-08-6
Молекулярная формула:C9H12N6S
Точка плавления:-
Smiles-код:C[C@H]1NCCN2C1=NN=C2C1=NC(C)=NS1
Плотность:
Номер в каталоге:CM1044501
Молекулярная масса:236.3
Точка кипения:
Номер Mdl:
Хранение:

Category Infos

Thiadiazoles
Thiadiazoles are a subfamily of azoles. Structurally, they are five-membered heterocyclic compounds containing two nitrogen atoms and one sulfur atom, and two double bonds, forming an aromatic ring. Depending on the relative positions of the heteroatoms, there are four possible structures; these forms do not interconvert and are therefore structural isomers rather than tautomers. These compounds themselves are rarely synthesized and have no particular utility, however, compounds that use them as structural motifs are fairly common in pharmacology.

Column Infos

Fezolinetant
Dec 10, 2023, VEOZA (fezolinetant) approved by European Commission for treatment of vasomotor symptoms associated with menopause.
VEOZAH is the first and only neurokinin 3 (NK3) receptor antagonist that blocks NKB from binding on KNDy neurons to help reduce heat signals that trigger VMS. First-in-class fezolinetant brings women a new nonhormonal therapy for hot flashes.
In May 2023, FDA has approved VEOZA(fezolinetant) 45 mg once daily for the treatment of moderate to severe VMS due to menopause.

Related Products